Pharmacogenomics in Australian community pharmacy

Integrating Pharmacogenomic Testing into Community Pharmacy Practice: Opportunities and Challenges is no longer a purely academic idea for Australian pharmacy. Tests examining genetic variants associated with medication metabolism can help explain why two patients taking the same standard dose may respond differently or experience toxicity. Community pharmacists are well placed to identify these differences at the point of dispensing, translate results into plain language and coordinate follow-up with prescribers and patients.

The value lies in supporting safer, more individualised treatment rather than replacing clinical judgement. Kidney function, age, other medicines, lifestyle and medical history still influence prescribing decisions. Pharmacogenomic testing works best as one source of information within a structured medication-management pathway, with clear consent, qualified interpretation and a documented plan for acting on the result.

Why community pharmacists are well placed to deliver

Community pharmacies are among the most accessible healthcare facilities in Australia. Patients routinely seek advice there when starting a medicine, changing a dose or managing a long-term condition. Pharmacists also see people whose medicines are supplied through the Pharmaceutical Benefits Scheme, often across multiple prescribers and healthcare services. This repeated contact creates opportunities to ask about previous reactions, family experiences and adherence barriers that might not appear in a brief consultation.

Testing can inform several familiar prescribing decisions. CYP2C19 results may help a clinician assess whether clopidogrel is likely to provide adequate antiplatelet activity. CYP2C9 and VKORC1 results can contribute to warfarin dose selection, while DPYD results may influence management of fluoropyrimidine medicines such as capecitabine or 5-fluorouracil. Such findings may prompt a prescriber to select an alternative medicine, adjust the dose or monitor more closely.

Patient-facing material should connect genetic findings with practical medication decisions rather than presenting genes as destiny. General preventive health guidance can support broader discussion, while test-specific information should come from the reporting laboratory, the treating clinician and applicable Australian guidance. Pharmacists are particularly valuable in correcting misconceptions that a result guarantees either safety or harm.

A practical clinical pathway for Australian pharmacies

A safe pathway normally begins with an appropriate clinical indication and informed consent. In many cases, a general practitioner assesses the patient, orders the test from an appropriately accredited laboratory and arranges any required genetic counselling. The patient can then consent to sharing the report with the community pharmacist. Private testing may accelerate access, but it does not remove the need for a qualified clinician to interpret the result and authorise changes to treatment.

Once the result is available, the pharmacist can review it alongside the medication list, allergies, previous adverse reactions and relevant clinical information. The pharmacist can explain the result, identify possible medication implications and ask the prescriber to consider a change. Home Medicines Reviews, MedsCheck services and medication reviews in aged care provide natural opportunities to incorporate this process without creating an entirely separate consultation.

The communication skills required for pharmacogenomic counselling already appear in other Australian pharmacy services. Pharmacists’ growing involvement in HIV prevention and treatment, including PrEP and PEP access, illustrates how accessible pharmacies can provide sensitive education, preventive advice and coordinated referrals. Pharmacogenomic consultations will require similar attention to privacy, health literacy and non-judgemental communication.

Scope must remain consistent with state legislation and professional requirements. Prescribing authority, delegation arrangements and the ability to order certain tests differ between jurisdictions, including New South Wales and Victoria. Pharmacists should establish local referral relationships and document who is responsible for each decision. A result should never trigger an unsupervised medication change.

Designing a service patients can understand and use

The funding model is a major practical issue. Medicare may contribute to an eligible medical consultation, but a dedicated pharmacogenomic pharmacist consultation is not usually covered by the Medicare Benefits Schedule, and pharmacogenomic tests are not routinely PBS-listed. Many patients therefore pay privately. A community pharmacy should publish the consultation fee, testing costs and any follow-up charges before booking, avoiding surprises during an already complex care episode.

Operational safeguards are equally important. The pharmacy needs a process for verifying the laboratory, recording consent, securely storing reports and separating clinical information from unrelated commercial data. Any software or device used to support ordering or interpretation should be assessed against applicable Australian regulatory requirements. Staff also need a defined pathway for urgent findings, inconclusive results and situations requiring referral to a genetic counsellor or specialist.

Standards should be consistent, even when testing is arranged privately. Pharmacists can work with laboratories, general practitioners, the Pharmaceutical Society of Australia and the Australian Pharmacists Association to develop templates that identify the relevant gene, phenotype or prescribing implication. Policy development also benefits from wider professional pharmacy commentary, particularly where funding, workforce capability and regulation must be considered together.

Interpreting results without overclaiming

A laboratory report may use terminology that is unfamiliar to patients. A useful consultation moves from the genetic result to its functional meaning, then to a medication recommendation and a monitoring plan. International prescribing guidelines, such as those developed by the Clinical Pharmacogenetics Implementation Consortium, can support decision-making, but they should be interpreted alongside Australian product information and current local guidance. A “normal metabolism” label does not mean that every dose is suitable for every person.

Polypharmacy makes this interpretation more complex. A patient taking several medicines may have several relevant results, while kidney impairment, liver disease or a recent medicine change may have a larger immediate effect. Pharmacists should avoid letting a genetic explanation displace simpler causes of an adverse reaction. They should also record when a result is unavailable, when evidence is uncertain and when a medicine may be started only after further assessment.

Automation can support, but cannot replace, professional review. Decision-support tools may quickly flag a gene–medicine pair, yet the quality of their reference data, population coverage and software logic can vary. Pharmacists should check the source and currency of each recommendation, discuss options with the prescriber and arrange follow-up. Patients benefit from a written summary stating whether the medicine should continue, change or be monitored and when the next review is due.

Equity, ethics and a credible path to scale

Cost can determine who receives useful information. Patients in Melbourne, Sydney, Brisbane and Perth may encounter multiple private testing offers with different prices and follow-up arrangements, while people in regional, rural and remote areas face additional travel and connectivity barriers. Telehealth can improve access, but it does not solve broadband limitations, time-zone differences or the need for culturally safe care. A service in the Northern Territory, for example, should be designed with local clinicians and communities rather than transplanted from a metropolitan model.

Aboriginal and Torres Strait Islander patients require particular care because genomic information carries implications beyond the individual. Research and clinical projects should be governed with community participation, appropriate consent processes, cultural safety and clear arrangements for data governance and benefit sharing. Projects should not assume that general population datasets accurately represent every Australian population. Genuine equity also requires affordable access, accessible interpreters and support for people with limited digital confidence.

Privacy must be explained before a test is ordered. Depending on the service and location, the Privacy Act 1988, state health-records legislation and the My Health Records Act 2012 may all be relevant. Patients should understand where the sample and report will be stored, who can access them, whether results can be uploaded to My Health Records and how information about biological relatives may be affected. Community pharmacists can make privacy practical by offering document-free consultations where appropriate, using secure systems and explaining that a patient may choose who receives the report.

Community pharmacy leaders should establish a defined pilot built around a clear clinical use case, accredited testing, agreed referral pathways, transparent fees and documented follow-up. Partnering with local general practitioners, pathology providers and genetic counsellors will be essential, while pharmacist training should cover genetic concepts, result limitations and communication. Measures should include referral completion, prescriber response time, medication changes, avoided adverse events and patient understanding. A successful pilot should then be evaluated, refined and expanded. The immediate priority is to turn pharmacogenomic testing into a reliable pharmacy service that Australian patients can access with informed consent, equitable pricing and a clear plan for action.